Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Is L'Oréal more reliable than the French government? Sell-off of French government bonds causes an inversion phenomenon, with yields of nearly 40% of high-rated corporate bonds lower than those of sovereign bonds.

Is L'Oréal more reliable than the French government? Sell-off of French government bonds causes an inversion phenomenon, with yields of nearly 40% of high-rated corporate bonds lower than those of sovereign bonds.

智通财经智通财经2026/10/08 09:16
Show original

Amid the sell-off of French government bonds, 215 billion euros worth of corporate bonds now yield less than government bonds, with the scale increasing 18 times this year as investors turn to high-quality corporate debt for risk aversion.

Zhituo Finance APP has noted that after a brutal sell-off of government bonds, nearly €215 billion (about $241 billion) worth of French corporate bonds are now trading at prices below those of government bonds with the same term—meaning they are considered safer than government bonds. This scale has grown nearly 18 times since early 2026.

According to compiled data, about 38% of the total high-grade French corporate bonds yielded lower than government bonds of the same maturity as of Wednesday. At the beginning of the year, this figure was just €12 billion.

This phenomenon, which upends the traditional market hierarchy, is not entirely new, but it has escalated rapidly in France. Market concerns are focused on the missed deficit targets, the deadlock over the new budget, and the looming presidential election, which could steer France in a vastly different direction.

As confidence in government bonds has eroded, corporate bonds—especially those from companies with significant international business like L'Oréal and oil and gas giant TotalEnergies—have now become among the safest havens.

Is L'Oréal more reliable than the French government? Sell-off of French government bonds causes an inversion phenomenon, with yields of nearly 40% of high-rated corporate bonds lower than those of sovereign bonds. image 0

In France, corporate debt is increasingly becoming a safe asset

Elisa Belgacem, senior credit strategist at Generali Investments, said, “France’s sovereign story and the corporate credit story have become increasingly disconnected.” Corporates and banks “continue to enjoy strong investor demand, highlighting market confidence in issuers’ fundamentals and the appeal of total yields.”

Paris-based Air Liquide is the latest example. On Tuesday, this industrial gas manufacturer issued €2 billion in bonds, attracting around €12.5 billion in investor orders, with both fixed-rate tranches yielding below those of French government bonds.

For Edward Farley, head of European investment grade corporate bonds at PGIM, the key factor is where companies’ revenues originate. Take L'Oréal and LVMH as examples: “Aside from being registered in France, the French factor is pretty much the only influence on them,” he said.

However, Farley is more cautious on French banks, as they are more closely linked to the government bond market. Whether by directly holding sovereign debt or being indirectly exposed to economic policy through lending, banks are intimately connected to national risk. The cost of default insurance for French bank bonds has now soared above that of other European peers.

Extreme Cases

Although France is an extreme case of corporate bond yields inverting with government bond yields, this dynamic has been brewing among developed economies for some time.

Traditionally, sovereign debt serves as the benchmark for bond market safety, because governments can increase taxes if they run short of funds. But as deficits swell and politicians across the spectrum struggle to rein them in, companies with strong balance sheets and strict financial discipline have instead become better bets.

Last year, Microsoft briefly saw its bond trading costs dip below those of US Treasuries, as markets worried about the fiscal impact of US tax cuts. Even earlier, during the Eurozone sovereign debt crisis, some Spanish and Italian corporate bonds were cheaper than their respective countries’ government debt—a situation more commonly faced by emerging market investors.

In France, since President Macron announced a snap election after his defeat in the European Parliament elections in mid-2024, political uncertainty has been a persistent theme in the bond market. By the end of that year, a few companies' bond yields had already fallen below those of French government bonds (OATs).

But this phenomenon is now much more widespread, and the scale of the corporate bond yield inversion may continue to grow. With more than six months to go until the French presidential election, the sell-off in government bonds has already begun to spill over to other markets.

Barclays credit strategist Melissa McCallum observed that the typical scenario of the domestic government bond yield curve acting as a floor for the credit market “may fail during periods of sovereign stress.”

“But it’s notable that it’s not just high-grade corporate bonds breaking through the OAT curve; many BBB-rated bonds have also narrowed their spreads below it,” she said.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Better Home & Finance shares rise after announcing a $30 million stock buyback plan

October 8 - Better Home & Finance (BETR.O), a mortgage and home equity financing company, saw its stock price rise 3.8% to $10.30 in pre-market trading after announcing a share repurchase plan. BETR stated that its board of directors has approved a stock buyback program of up to $30 million, with an initial phase of $10 million to kick off the repurchase. The company plans to adjust the pace of the repurchase based on realized operational cost savings and asset disposal progress, such as the proposed sale of its UK bank subsidiary. The buyback program is set to expire on October 8, 2027. In August, BETR forecasted that its Q3 revenue would be below Wall Street expectations as it focuses on partnership opportunities and accelerating the development of its home equity credit business. As of the previous trading day's close, the company's market capitalization was approximately $175 million. As of Wednesday, the stock has dropped about 70% year-to-date. According to LSEG data, seven out of eight analysts rate the stock as "strong buy" or "buy," with one rating it as "hold"; the median target price is $25. (For the convenience of non-English speakers, Reuters provides translated automated reports in several other languages. As automated translations may contain errors or lack required context, Reuters does not guarantee the accuracy of these texts and provides them simply for convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)

路透社•2026/10/08 13:36

Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.

Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.

智通财经•2026/10/08 13:18
Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.

Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.

The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)

路透社•2026/10/08 12:56